Cargando…

Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer

Among the three primary gynecological malignancies, ovarian cancer has the lowest incidence but the worst prognosis. Because of the poor prognosis of ovarian cancer patients treated with existing treatments, immunotherapy is emerging as a potentially ideal alternative to surgery, chemotherapy, and t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Xukai, Shen, Yini, Huang, Wu, Bao, Yiting, Mo, Jiahang, Yao, Liangqing, Yuan, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	An Inventory of Epithelial Ovarian Cancer Targets: “Evidence-based” Options-Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969460/ https://www.ncbi.nlm.nih.gov/pubmed/36826231 http://dx.doi.org/10.1177/10732748231159706

Ejemplares similares

RoBERTa-Assisted Outcome Prediction in Ovarian Cancer Cytoreductive Surgery Using Operative Notes
por: Laios, Alexandros, et al.
Publicado: (2023)

The Prognostic Significance of Adjuvant Chemotherapy in Adult Ovarian Granulosa Cell Tumors: A Systematic Review and Meta-analysis
por: Zhuang, Yuan, et al.
Publicado: (2023)

The Use of Artificial Intelligence for Complete Cytoreduction Prediction in Epithelial Ovarian Cancer: A Narrative Review
por: Parpinel, Giulia, et al.
Publicado: (2023)

The Significance of Radiotherapy in Ovarian Clear Cell Carcinoma: A Systematic Review and Meta-Analysis
por: Zhuang, Yuan, et al.
Publicado: (2023)

The Future of AI in Ovarian Cancer Research: The Large Language Models Perspective
por: Laios, Alexandros, et al.
Publicado: (2023)

Prognostic Value of En-Block Radical Bowel Resection in Advanced Ovarian Cancer Surgery With HIPEC
por: Panoskaltsis, T., et al.
Publicado: (2023)

Immune-Related Genes’ Prognostic, Therapeutic and Diagnostic Value in Ovarian Cancer Immune-Related Gene Biomarker in Ovarian Cancer
por: Ding, Bo, et al.
Publicado: (2023)

Survival Outcomes of Patients with International Federation of Gynecology and Obstetrics Stage IV Ovarian Cancer: Cytoreduction Still Matters
por: Xiao, Yao, et al.
Publicado: (2023)

High Pretreatment Plasma D-dimer Levels Are Associated With Poor Prognosis in Patients With Ovarian Cancer Independently of Venous Thromboembolism and Tumor Extension
por: Sakurai, Manabu, et al.
Publicado: (2015)

Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study
por: Sayal, Karen, et al.
Publicado: (2015)

Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers
por: Sölétormos, György, et al.
Publicado: (2016)

Risk of Ovarian Cancer Relapse Score: A Prognostic Algorithm to Predict Relapse Following Treatment for Advanced Ovarian Cancer
por: Rizzuto, Ivana, et al.
Publicado: (2015)

Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials
por: Friedlander, Michael L., et al.
Publicado: (2016)

Differences in Clinical and Biological Features Between Type I and Type II Tumors in FIGO Stages I-II Epithelial Ovarian Carcinoma
por: Skirnisdottir, Ingiridur, et al.
Publicado: (2015)

Pure Immature Teratoma of the Ovary in Adults: Thirty-Year Experience of a Single Tertiary Care Center
por: Alwazzan, Ahmad Bakr, et al.
Publicado: (2015)

Understanding Lymphatic Drainage Pathways of the Ovaries to Predict Sites for Sentinel Nodes in Ovarian Cancer
por: Kleppe, Marjolein, et al.
Publicado: (2015)

Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study
por: Oza, Amit M., et al.
Publicado: (2017)

Expression of Tissue Factor in Epithelial Ovarian Carcinoma Is Involved in the Development of Venous Thromboembolism
por: Sakurai, Manabu, et al.
Publicado: (2017)

Applying Precision Medicine to Ovarian Cancer: Proof-of-Principle for a “Molecular Second Look”
por: Schwartz, Melissa, et al.
Publicado: (2018)

Cellular Senescence in the Treatment of Ovarian Cancer
por: Wang, Zehua, et al.
Publicado: (2018)

Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials
por: Wang, Haihong, et al.
Publicado: (2018)

Short-term Outcomes and Pregnancy Rate After Laparoscopic Fertility-Sparing Surgery for Borderline Ovarian Tumors: A Single-Institute Experience
por: Zhao, Jianguo, et al.
Publicado: (2018)

Uterine and Tubal Lavage for Earlier Cancer Detection Using an Innovative Catheter: A Feasibility and Safety Study
por: Maritschnegg, Elisabeth, et al.
Publicado: (2018)

The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer
por: Zhu, Xinxin, et al.
Publicado: (2018)

Genetics Consultation Rates Following a Diagnosis of High-Grade Serous Ovarian Carcinoma in the Canadian Province of Ontario
por: McGee, Jacob, et al.
Publicado: (2017)

Impact of Recurrence of Ovarian Cancer on Quality of Life and Outlook for the Future
por: Colombo, Nicoletta, et al.
Publicado: (2017)

Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer
por: Krell, Daniel, et al.
Publicado: (2017)

Factors Predicting Use of Neoadjuvant Chemotherapy Compared With Primary Debulking Surgery in Advanced Stage Ovarian Cancer—A National Cancer Database Study
por: Leiserowitz, Gary S., et al.
Publicado: (2017)

Modulation of non-coding RNAs by resveratrol in ovarian cancer cells: In silico analysis and literature review of the anti-cancer pathways involved
por: Vallino, Letizia, et al.
Publicado: (2020)

Differential effects of thymoquinone on lysophosphatidic acid-induced oncogenic pathways in ovarian cancer cells
por: Ha, Ji Hee, et al.
Publicado: (2020)

Insights into CD47/SIRPα axis-targeting tumor immunotherapy
por: Zhang, Xuyao, et al.
Publicado: (2018)

Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis
por: Hu, Jinyang, et al.
Publicado: (2020)

Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy
por: Zhao, Pengcheng, et al.
Publicado: (2023)

Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and target for cancer immunotherapy
por: Logtenberg, Meike E. W., et al.
Publicado: (2019)

New ways of assessing ovarian cancer response: metabolic imaging and beyond
por: Rockall, Andrea, et al.
Publicado: (2012)

Recent advances in systemic treatments for ovarian cancer
por: Banerjee, Susana, et al.
Publicado: (2012)

CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies
por: Bouwstra, Renée, et al.
Publicado: (2022)

Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy
por: Zhang, Jin, et al.
Publicado: (2018)

CD47/SIRPα axis: bridging innate and adaptive immunity
por: van Duijn, Anneloes, et al.
Publicado: (2022)

Promising alternatives of CD47 monoclonal antibody: an injectable degradable hydrogel loaded with PQ912 for postoperative immunotherapy effectively blocks CD47-SIRPα signal
por: Li, Chang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g0fo5uatcds30l20ocov2h75ga